Pancreatic Cancer Research

ResearcherJesse Brown VA Medical CenterActive in the last 2 years

Hidayatullah G. Munshi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9552-0775; OpenAlex author ID A5001372566; NIH RePORTER profile ID 6683019. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 16)
Trials
0
Grants
9
Labs led
2
Collaborators
42
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 1 paper, 1 grant · 2014: 1 paper · 2015: 1 paper, 1 grant · 2016: 3 papers · 2017: 1 grant · 2018: 1 paper · 2019: 1 paper · 2020: 1 grant · 2021: 4 papers · 2022: 4 papers, 2 grants · 2023: 1 paper, 1 grant · 2024: 2 papers · 2025: 1 grant · 2026: 1 paper, 1 grant

Papers 28

  1. Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. Co-author DOI 10.1021/acschembio.6c00580↗
  2. Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-3574↗
  3. Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. Last author DOI 10.1158/1535-7163.mct-23-0833↗
  4. Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer. Last author DOI 10.3390/cells12111490↗
  5. Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. Last author DOI 10.1016/j.celrep.2022.110441↗
  6. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2116764119↗
  7. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Co-author DOI 10.1073/pnas.2200143119↗
  8. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.806963↗
  9. Trials and tribulations of pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.canlet.2021.01.031↗
  10. Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. Co-author DOI 10.1021/acsmedchemlett.1c00376↗
  11. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Co-author DOI 10.3389/fonc.2021.688377↗
  12. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Last author DOI 10.3390/cancers13030440↗
  13. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-18-0850↗
  14. KRAS G12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Co-author DOI 10.1038/s41598-018-30916-6↗
  15. Interaction of tRNA with MEK2 in pancreatic cancer cells. Last author DOI 10.1038/srep28260↗
  16. Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia. Last author DOI 10.1038/srep29133↗
  17. Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-15-0285↗
  18. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Last author DOI 10.1038/srep09489↗
  19. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Last author DOI 10.1158/1535-7163.mct-13-0925↗
  20. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. Last author DOI 10.1371/journal.pone.0064566↗
  21. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. Co-author DOI 10.1016/j.jss.2011.09.020↗
  22. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Last author DOI 10.1042/bj20111240↗
  23. Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. Last author DOI 10.1074/jbc.m111.308940↗
  24. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Co-author DOI 10.1136/gutjnl-2011-300821↗
  25. Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Last author DOI 10.1038/onc.2010.485↗
  26. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. Last author DOI 10.1074/jbc.m110.195628↗
  27. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Last author DOI 10.1158/0008-5472.can-10-1855↗
  28. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Co-author DOI 10.1586/era.11.125↗

Grants 9

  1. Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer R01CA265997↗
  2. Role of MNK kinase pathway in regulating tumor immune microenvironment in pancreatic cancer I01BX005595↗
  3. Ex vivo slice cultures of mouse pancreatic tumors to test novel regimens I21BX005693↗
  4. Galpha13 and pancreatic cancer progression R01CA217907↗
  5. Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures. R21CA255291↗
  6. Targeting MNK Pathways in Pancreatic Cancer I01BX002922↗
  7. Targeting BET Bromodomain in Pancreatic Cancer R01CA186885↗
  8. Targeting stromal reaction in pancreatic cancer to overcome chemo-resistance I01BX001363↗
  9. Fibrosis-Protease Cross-Talk Regulating Pancreatic Cancer Invasion R01CA126888↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thao D. Pham · 8 shared papers, 2021–2026 · strength 1.52
  2. Daniel R. Principe · 9 shared papers, 2018–2024 · strength 1.28
  3. Mario A. Shields · 9 shared papers, 2011–2024 · strength 0.95
  4. Ajay Nmn Rana · 7 shared papers, 2018–2022 · strength 0.92
  5. David J. Bentrem · 12 shared papers, 2011–2024 · strength 0.91
  6. Jeffrey H. Becker · 3 shared papers, 2024–2026 · strength 0.76
  7. Patrick W. Underwood · 5 shared papers, 2021–2022 · strength 0.72
  8. Jose Gilberto Trevino · 4 shared papers, 2021–2022 · strength 0.58
  9. Karl A. Scheidt · 2 shared papers, 2021–2026 · strength 0.49
  10. Krishan Kumar · 6 shared papers, 2013–2023 · strength 0.47
  11. Sandeep Kumar · 3 shared papers, 2019–2022 · strength 0.40
  12. Kazumi Ebine · 6 shared papers, 2013–2016 · strength 0.33
  13. Murray Korc · 2 shared papers, 2021 · strength 0.33
  14. Gina M. Connors · 1 shared paper, 2026 · strength 0.32
  15. Paul J. Grippo · 6 shared papers, 2011–2019 · strength 0.31
  16. Suneel Deepak Kamath · 2 shared papers, 2021–2022 · strength 0.30
  17. Surabhi Y. Dangi-Garimella · 8 shared papers, 2011–2013 · strength 0.29
  18. Dhavan Shah · 1 shared paper, 2024 · strength 0.22
  19. Rosa F. Hwang · 1 shared paper, 2023 · strength 0.20
  20. Seth B. Krantz · 6 shared papers, 2011–2012 · strength 0.20
  21. Ada Jade Kwong · 1 shared paper, 2021 · strength 0.17
  22. Carolina Torres · 2 shared papers, 2018–2019 · strength 0.16
  23. Jose Trevino · 1 shared paper, 2022 · strength 0.14
  24. Dinesh Thummuri · 1 shared paper, 2022 · strength 0.13
  25. Daohong Zhou · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.